Global Orphan Drugs Market Research Report 2023: Market to Reach $415.2 Billion by the End of 2028 – Premium Pricing of Orphan Drugs and Increasing Collaborations/Licensing Agreements Bolsters Growth
DUBLIN, Jan. 17, 2024 /PRNewswire/ — The “Global Markets for Orphan Drugs” report has been added to ResearchAndMarkets.com’s offering.
The global orphan drugs market was valued at an estimated $233.9 billion in 2023. This market is projected to reach $415.2 billion by the end of 2028, growing at a CAGR of 12.2% during the forecast period. Growth factors include the increased involvement of pharmaceutical companies in developing orphan drugs, the growing number of new approvals and the increased global availability of these drugs.
Orphan drugs have paved the way for the treatment of the many unmet clinical and therapeutic needs of patients with orphan and rare diseases such as Gaucher’s disease, Pompe disease, cystic fibrosis, Hunter syndrome, tuberous sclerosis complex and chronic myelogenous leukemia. These developments have spurred pharmaceutical and biotech companies such as Roche, Novartis, GlaxoSmithKline, Johnson & Johnson, Bristol-Myers Squibb, Merck & Co., and Pfizer to invest in and develop orphan and rare disease therapies and drugs.
In contrast to developing drugs for prevalent disorders, creating medications for orphan diseases can be more difficult. Pharmaceutical companies face several fundamental challenges when developing orphan drugs such as a lack of standard comparator drugs, a lack of clear understanding of pathophysiology or natural history, a lack of scientific evidence, and a lack of validated preclinical models.
The small patient pool presents challenges that frequently lead to inadequate patient participation and impact the evaluation of clinical trial outcomes in patients with rare diseases. These patients frequently exhibit a great deal of variability in their clinical presentation and histories, with factors such as age, disease severity, and progression influencing reported outcomes.
The orphan drug market has emerged as a niche business of the pharmaceutical industry. This market’s primary growth factors include incentives for orphan drug sponsors, tax breaks, market exclusivity, grants programs for clinical studies, funds for the development of orphan products, and multiple indication approvals. The sequencing of the human genetic code, which created a better understanding of human metabolism and the role of genetics in the manifestation of disease, also played a significant role in the development of the orphan drug market.
By region, North America dominates the global orphan drug market due to growth factors such as advanced healthcare infrastructure and the U.S. Food and Drug Administration (FDA)-sponsored grant programs for the development of potential therapeutic compounds through its Office of Orphan Products Development (OOPD). The European market, with its well-established orphan drug legal framework, is also expanding. Growth factors include multiple post-market safety and efficacy clinical trials and the commission of potential orphan drugs through patient networks such as the European Organization for Rare Diseases (EURORDIS).
The Asia-Pacific pharmaceutical market offers potential as countries such as Japan, Taiwan, and South Korea have implemented legal legislations akin to the U.S. Orphan Drug Act. The main growth factors in this emerging regional market are patient awareness programs, global connectivity through rare disease patient organizations and the availability of orphan drugs through joint collaborations.
Report Includes
33 data tables and 46 additional tablesOverview and an up-to-date analysis of the global markets for orphan drugs (ODs) for rare diseases treatmentAnalyses of the global market trends, with historical market revenue data (sales figures) from 2021 to 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028Highlights of the current and future market potential of orphan drugs, along with a detailed analysis of the market drivers, restraints, and opportunitiesEstimate of the actual market size and revenue forecast for the global orphan drugs market, and its corresponding market share analysis based on the product type, therapeutic area, and regionAnalysis of market growth opportunities with a holistic review of Porter’s five forces model and PESTLE analyses considering the microand macroeconomic factors prevailing in the marketplaceDiscussion of sustainability trends and factors in the orphan drugs market, with emphasis on consumer attitudes, ESG score analysis, future of ESG, case study, and the ESG practices followedAnalyses of the novel therapeutic applications of orphan drugs in rare and orphan diseases as well as examination of the regulatory framework, patents, and recent innovations in the industryReview of the current status and trends in clinical trials for the development of drugs in rare diseases among the three registries from the U.S., EU and JapanDiscussion of successful orphan medicinal products, rising influence of pharmacogenomics in the ODs market, information on specific rare diseases for which orphan drugs existAssessment of the most promising therapeutic areas in the industry and leading orphan drugs in these areasOverview of the industry structure for orphan drugs, pricing and reimbursement policies, COVID-19 impact, and market share analysis of the leading manufacturers of orphan drugs along with their SWOT analysesCompany profiles of major players within the industry, including AstraZeneca Plc, Eisai Co. Ltd., Bristol Myers Squibb and Pfizer Inc.
Company Profiles
Abbvie Inc.Astellas Pharma Inc.Astrazeneca PlcBristol Myers SquibbEisai Co. Ltd.Eli Lilly And Co.F. Hoffmann-La Roche Ltd.Merck & Co. Inc.Novartis AgPfizer Inc.Sanofi S.A.Takeda Pharmaceutical Co. Ltd.
Key Topics Covered:
Chapter 1 Introduction
Study Goals and ObjectivesReasons for Doing This StudyScope of ReportWhat’s New in this Update?MethodologyInformation SourcesGeographic BreakdownSegmentation Breakdown
Chapter 2 Summary and Highlights
Market OutlookMarket Summary
Chapter 3 Market Overview
Market and Technology BackgroundGlobal Definitions of Rare Diseases by Country/RegionU.S.EUTaiwanJapanAustraliaSingaporeSouth KoreaSwitzerlandBrazil
Chapter 4 Market Dynamics
OverviewDriversFavorable Orphan Drug Act and Similar LegislationTechnological Advances in GenomicsLack of Competition from Generic DrugsPatent ExtensionsPremium Pricing of Orphan DrugsInnovations in Manufacturing TechnologiesIncreasing Collaborations and Licensing AgreementsRestraintsLack of Trained ProfessionalsVulnerable Target GroupsRegulatory ChallengesOpportunitiesHuge Product Pipeline of New Orphan DrugsRegulatory LandscapeU.S.EuropeJapanTaiwanSouth Korea
Chapter 5 Global Market for Orphan Drugs by Product Type
Biological Orphan DrugsNon-biological Orphan Drugs
Chapter 6 Global Market for Orphan Drugs by Therapeutic Application
OncologyBlood DisordersCentral Nervous SystemRespiratory SystemImmunomodulatorsCardiovascular TherapiesEndocrine SystemMusculoskeletal SystemOthers
Chapter 7 Global Market for Orphan Drugs by Region
Global Market Share AnalysisNorth AmericaEuropeAsia-PacificRest of the World (RoW)
Chapter 8 ESG Outlook in the Orphan Drugs Market
Introduction to ESGImportance of ESG in the Orphan Drug IndustryESG Pillars in the Orphan Drugs IndustryESG Ratings and Metrics: Understanding the DataESG practices in the Orphan Drug IndustryConcluding Remarks
Chapter 9 Orphan Drugs Exclusivity and Pricing Policies
Reimbursed Price of ODs: Current Strategies and Potential ImprovementsComprehensive Value AssessmentEarly DialoguesInnovative Reimbursement ApproachesSocietal Participation in Producing ODs
Chapter 10 Clinical Trials on Drugs for Rare Diseases
List of Clinical Trials on Drugs for Rare Diseases
Chapter 11 Competitive Landscape
Top 10 Selling Orphan Drugs GloballyMarket Share Analysis
For more information about this report visit https://www.researchandmarkets.com/r/b9mb4o
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
You may also like
Kyverna Therapeutics Congratulates Prof. G. Schett et al. on the Publication of a Case Series Follow-up of 15 Patients Living with Autoimmune Disease Treated With CAR T-Cell Therapy
The paper reports on a series of 15 patients with severe rheumatological autoimmune diseases that we
Colt DCS launches Central Telemetry Platform, providing customers with real-time performance analysis for cost savings, efficiencies and sustainable outcomes
LONDON, March 21, 2024 /PRNewswire/ — Colt Data Centre Services (Colt DCS), a global provider
Global Nafion Market on the Rise: Forecasts a 5.5% CAGR to 2030 with Noteworthy Advancements in Renewable Energy Technologies
DUBLIN, Feb. 26, 2024 /PRNewswire/ — The “Nafion Market Report: Trends, Forecast and Com
